2型糖尿病患者中的干细胞来源胰岛移植:糖尿病亚型能否指导实施?
本文综述了干细胞来源胰岛移植(SC-ITx)及无免疫抑制移植的进展,提出可能扩大受者人群。同时介绍ANDIS分类系统将糖尿病分为5种亚型,各具独特病因与结局。作者基于全胰腺移植证据及20余年胰岛移植经验,探讨按新亚型评估SC-ITx的考量、局限及需考虑的移植特征,并提出推荐与研究方向。
要点
- 历史上仅脆性糖尿病或严重反复低血糖患者考虑胰岛移植,以优化风险获益。
- 干细胞来源胰岛移植及无免疫抑制移植可能使更广泛受者人群的考量合理化。
- ANDIS分类系统描述5种糖尿病亚型,各具独特病因与结局,挑战经典分类。
核心结论
- 基于全胰腺移植受者证据及作者20余年胰岛移植经验,作者提出推荐和潜在研究路径,以论证在更广泛的全类型糖尿病患者中实施干细胞来源胰岛移植。
研究设计与样本
- 本文为综述,检索范围未在原文摘要中报告。
主要发现
- 历史上仅脆性糖尿病或严重反复低血糖患者被考虑胰岛移植,以优化风险获益并考虑长期免疫抑制风险和有限器官供应。
- 干细胞来源胰岛移植及无免疫抑制移植的出现可能使更广泛受者人群的考量合理化。
- ANDIS分类系统描述5种糖尿病亚型,各具独特病因与结局。
关键数值与推荐
- 原文未报告具体推荐条款或数值标准。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Historically, only patients with brittle diabetes or severe recurrent hypoglycemia have been considered for islet transplantation (ITx). This population has been selected to optimize the risk-benefit profile, considering risks of long-term immunosuppression and limited organ supply. However, with the advent of stem cell (SC)-derived ITx and the potential for immunosuppression-free ITx, consideration of a broader recipient cohort may soon be justified. Simultaneously, the classical categorization of diabetes is being challenged by growing evidence in support of a clustering of disease subtypes that can be better categorized by the All New Diabetics in Scania (ANDIS) classification system. Using the ANDIS classification, 5 subtypes of diabetes have been described, each with unique causes and consequences. We evaluate consideration for ITx in the context of this broader patient population and the new classification of diabetes subtypes. In this review, we evaluate considerations for ITx based on novel diabetes subtypes, including their limitations, and we elaborate on unique transplant features that should now be considered to enable ITx in these "unconventional" patient cohorts. Based on evidence from those receiving whole pancreas transplant and our more than 20-year experience with ITx, we offer recommendations and potential research avenues to justify implementation of SC-derived ITx in broader populations of patients with all types of diabetes.
引用
- Verhoeff K, Marfil-Garza BA, Czarnecka Z, et al. Stem Cell-Derived Islet Transplantation in Patients With Type 2 Diabetes: Can Diabetes Subtypes Guide Implementation? J Clin Endocrinol Metab. 2023. PMID: 37170783. doi:10.1210/clinem/dgad257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。